⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17080155 | 0.97 | — | — | |
| SCHEMBL18225231 | 0.80 | — | — | |
| SCHEMBL2220312 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL10702462 | 0.78 | — | — | |
| SCHEMBL8980786 | 0.78 | — | — | |
| SCHEMBL4772403 | 0.77 | — | — | |
| SCHEMBL13145799 | 0.77 | HTR7 (0.36) | — | |
| SCHEMBL14099264 | 0.77 | SCN1A (0.42) | — | |
| SCHEMBL173416 | 0.77 | — | — | |
| SCHEMBL15867718 | 0.75 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110092788-B | Substituted [1,2,4] triazolo [1,5-a ] pyrimidin-7-yl compounds as PDE2 inhibitors | 达特神经科学(开曼)有限公司 | 2022-02-25 | — | — | CN | claimed |
| EP-3597649-B1 | COMPOSITIONS CONTAINING SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2021-10-13 | — | — | EP | claimed |
| EP-3134413-B1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-09-11 | — | — | EP | claimed |
| US-9932345-B2 | Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-04-03 | — | — | US | claimed |
| US-20170057967-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC | 2017-03-02 | — | — | US | claimed |
| EP-3134413-A1 | SUBSTITUTED [1,2,4]TRIAZOLO [1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | Dart Neuroscience (Cayman) Ltd (KY) | 2017-03-01 | — | — | EP | claimed |
| WO-2015164508-A1 | SUBSTITUTED [1,2,4] TRIAZOLO [1,5-A] PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2015-10-29 | — | — | WO | claimed |
| US-20140206679-A1 | HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD (CN) | 2014-07-24 | — | — | US | claimed |
| CN-103275091-A | Ixabepilone total synthesis | SHENZHEN JATIE PHARMACEUTICAL CO LTD | 2013-09-04 | — | — | CN | claimed |
| CN-102686595-A | Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO | 2012-09-19 | — | — | CN | claimed |
| CN-102686596-A | Azabicyclo[2.2.1] heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO | 2012-09-19 | — | — | CN | claimed |
| US-8227606-B2 | Arginine derivatives with NP-1 antagonistic activity | ARK THERAPEUTICS, LTD. (GB) | 2012-07-24 | — | — | US | claimed |
| CN-102066384-A | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO | 2011-05-18 | — | — | CN | claimed |
| CN-1732172-A | Epothilone derivatives | NOVARTIS AG (CH) | 2006-02-08 | — | — | CN | claimed |
| US-20060014796-A1 | Epothilone derivatives | DENNI-DISCHERT DONATIENNE | 2006-01-19 | — | — | US | claimed |
| EP-1581536-A2 | EPOTHILONE DERIVATIVES | Novartis AG (CH) | 2005-10-05 | — | — | EP | claimed |
| WO-2004056832-A2 | EPOTHILONE DERIVATIVES | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | claimed |
| US-6646010-B2 | Enzyme inhibitors such as N(3-benzyloxycarbonylamino-2-hydroxy -4-phenylbutyl)-N-isoamylamine, used for prophylaxis of viral diseases and infections; lymphadenopathy associated virus | G. D. SEARLE & CO. | 2003-11-11 | — | — | US | claimed |
| US-5541299-A | Process for the preparation of dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1996-07-30 | — | — | US | claimed |
| US-12630556-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors | DART NEUROSCIENCE LLC (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250368636-A1 | NOVEL HETEROCYCLIC COMPOUND, SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION | THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) | 2025-12-04 | — | — | US | disclosed |
| US-20250092047-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC | 2025-03-20 | — | — | US | disclosed |
| CN-115054600-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-115996914-B | Novel heterocyclic compound and salt thereof, and luminescent substrate composition | 国立大学法人电气通信大学 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023238683-A1 | NOVEL HETEROCYCLIC COMPOUND AND SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION | 国立大学法人電気通信大学 | 2023-12-14 | — | — | WO | disclosed |
| WO-2023238683-A1 | NOVEL HETEROCYCLIC COMPOUND AND SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION | 国立大学法人電気通信大学 | 2023-12-14 | — | — | WO | disclosed |
| US-20230365549-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2023-11-16 | — | — | US | disclosed |
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-11807612-B2 | Heterocyclic compound and salt thereof, and luminescent substrate composition | THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) | 2023-11-07 | — | — | US | disclosed |
| US-11807612-B2 | Heterocyclic compound and salt thereof, and luminescent substrate composition | THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) | 2023-11-07 | — | — | US | disclosed |
| US-11807612-B2 | Heterocyclic compound and salt thereof, and luminescent substrate composition | THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) | 2023-11-07 | — | — | US | disclosed |
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4257587-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230192698-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192635-A1 | NOVEL HETEROCYCLIC COMPOUND AND SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION | THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192635-A1 | NOVEL HETEROCYCLIC COMPOUND AND SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION | THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192635-A1 | NOVEL HETEROCYCLIC COMPOUND AND SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION | THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-4180434-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2023-05-09 | — | — | US | disclosed |
| CN-115996914-A | Novel heterocyclic compound and salt thereof, and luminescent substrate composition | 国立大学法人电气通信大学 | 2023-04-21 | — | — | CN | disclosed |
| CN-110950860-B | Fused tricyclic compound and application thereof in medicines | 广东东阳光药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | BenevolentAl Bio Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| CN-115054600-A | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114984003-A | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2022117016-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳微芯生物科技股份有限公司 | 2022-06-09 | — | — | WO | disclosed |
| EP-3204378-B3 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2022-05-25 | — | — | EP | disclosed |
| CN-110092788-B | Substituted [1,2,4] triazolo [1,5-a ] pyrimidin-7-yl compounds as PDE2 inhibitors | 达特神经科学(开曼)有限公司 | 2022-02-25 | — | — | CN | disclosed |
| WO-2022004744-A1 | NOVEL HETEROCYCLIC COMPOUND AND SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION | 国立大学法人電気通信大学 | 2022-01-06 | — | — | WO | disclosed |
| US-11186582-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors | Dart Neuroscience, (Cayman) LTD. (KY) | 2021-11-30 | — | — | US | disclosed |
| EP-3597649-B1 | COMPOSITIONS CONTAINING SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2021-10-13 | — | — | EP | disclosed |
| EP-3865485-A1 | IMIDAZOPYRAZINE INHIBITORS OF BRUTON'S TYROSINE KINASE | Acerta Pharma B.V. (NL) | 2021-08-18 | — | — | EP | disclosed |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210046076-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2021-02-18 | — | — | US | disclosed |
| US-10793560-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2020-10-06 | — | — | US | disclosed |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| WO-2020108613-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业集团有限公司 | 2020-06-04 | — | — | WO | disclosed |
| CN-110950860-A | Fused tricyclic compound and application thereof in medicines | 广东东阳光药业有限公司 | 2020-04-03 | — | — | CN | disclosed |
| US-20200095256-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE, LLC | 2020-03-26 | — | — | US | disclosed |
| WO-2020041331-A1 | PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | ARVINAS OPERATIONS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| CN-110382494-A | Substituted pyrazolo [1,5-A ] pyridine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2019-10-25 | — | — | CN | disclosed |
| EP-3181564-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | HOFFMANN LA ROCHE (CH) | 2019-09-18 | — | — | EP | disclosed |
| EP-3134413-B1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-09-11 | — | — | EP | disclosed |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-05 | — | — | US | disclosed |
| CN-107108565-B | The N- pyridine yl acetamide derivatives of inhibitor as WNT signal transmission approach | 莱德克斯制药公共有限公司 | 2019-08-23 | — | — | CN | disclosed |
| EP-3204378-B1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2019-07-10 | — | — | EP | disclosed |
| US-20190153308-A1 | Dinuclear Organometallic Complex and Application Using Same | AAC MICROTECH(CHANGZHOU)CO.,LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20180319788-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2018-11-08 | — | — | US | disclosed |
| US-10029987-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| CN-108290838-A | Biaryl derivatives and drugs containing the same | 科研制药株式会社 | 2018-07-17 | — | — | CN | disclosed |
| US-20180179216-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC | 2018-06-28 | — | — | US | disclosed |
| US-9932345-B2 | Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-04-03 | — | — | US | disclosed |
| US-9890152-B2 | Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2017-09-28 | — | — | US | disclosed |
| CN-104955824-B | It is used as the aminopyrimidine compounds of the inhibitor of the EGFR mutant containing T790M | 豪夫迈·罗氏有限公司 | 2017-09-22 | — | — | CN | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| CN-107108565-A | The N pyridine yl acetamide derivatives of the inhibitor of approach are transmitted as WNT signals | 莱德克斯制药公共有限公司 | 2017-08-29 | — | — | CN | disclosed |
| EP-3204378-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | Redx Pharma PLC (GB) | 2017-08-16 | — | — | EP | disclosed |
| EP-2922851-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20170183311-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2017-06-29 | — | — | US | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| EP-3181564-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20170057967-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC | 2017-03-02 | — | — | US | disclosed |
| EP-3134413-A1 | SUBSTITUTED [1,2,4]TRIAZOLO [1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | Dart Neuroscience (Cayman) Ltd (KY) | 2017-03-01 | — | — | EP | disclosed |
| US-9562060-B2 | Heterocyclic pyridone compound, and intermediate, preparation method and use thereof | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD (CN) | 2017-02-07 | — | — | US | disclosed |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| WO-2016055786-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2016-04-14 | — | — | WO | disclosed |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20150329543-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-11-19 | — | — | US | disclosed |
| WO-2015164508-A1 | SUBSTITUTED [1,2,4] TRIAZOLO [1,5-A] PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2015-10-29 | — | — | WO | disclosed |
| EP-2922851-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| CN-104955824-A | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants | GENENTECH INC | 2015-09-30 | — | — | CN | disclosed |
| US-20150259342-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150259342-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150087652-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-03-26 | — | — | US | disclosed |
| US-20150087652-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-03-26 | — | — | US | disclosed |
| US-20140206679-A1 | HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD (CN) | 2014-07-24 | — | — | US | disclosed |
| WO-2014081718-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-8735417-B2 | Aminopyrimidines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140135342-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-20140135342-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| EP-2316839-B1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS HAVING PHOSPHONATE GROUPS | GILEAD SCIENCES INC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20130289046-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| US-20130289046-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| CN-103025744-A | Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs | BRISTOL MYERS SQUIBB CO | 2013-04-03 | — | — | CN | disclosed |
| US-20130030005-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130030005-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120309735-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-06 | — | — | US | disclosed |
| CN-102791718-A | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO | 2012-11-21 | — | — | CN | disclosed |
| EP-1363705-B9 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20120238583-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| US-20120238583-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| CN-102686595-A | Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO | 2012-09-19 | — | — | CN | disclosed |
| CN-102686596-A | Azabicyclo[2.2.1] heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO | 2012-09-19 | — | — | CN | disclosed |
| EP-2484342-A1 | Hair resiliency / body improver and hair cosmetic | Shiseido Company, Limited (JP) | 2012-08-08 | — | — | EP | disclosed |
| EP-1363705-B1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2455098-A1 | New cyclic peptide compounds | Astellas Pharma Inc. (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20120095017-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| US-20120095017-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| CN-101953755-B | Hair springiness and stiffness improving agent and hair cosmetic | SHISEIDO CO LTD | 2012-03-28 | — | — | CN | disclosed |
| US-20110245268-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-8008329-B2 | Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2011-08-30 | — | — | US | disclosed |
| EP-1778702-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20110118279-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-20110118279-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| CN-102066384-A | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO | 2011-05-18 | — | — | CN | disclosed |
| EP-2316839-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-05-04 | — | — | EP | disclosed |
| CN-101953755-A | The tension force of hair and toughness improving agent and hair-dressing cosmetics | SHISEIDO CO LTD | 2011-01-26 | — | — | CN | disclosed |
| CN-101343269-B | 1,2,3-thiadiazoles derivants, synthesis and use thereof | UNIV NANKAI | 2010-10-13 | — | — | CN | disclosed |
| US-20100120672-A1 | CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100120672-A1 | CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100093752-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-20100093752-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-20100069244-A1 | Pyridine Compounds for Combating Pests | BASF SE (DE) | 2010-03-18 | — | — | US | disclosed |
| US-7662823-B2 | Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662823-B2 | Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-16 | — | — | US | disclosed |
| US-20100029596-A1 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE | Dong Wha Pharm, Co. Ltd. (KR) | 2010-02-04 | — | — | US | disclosed |
| US-7642339-B2 | Hepatitis C; 1-benzyloxycarbonylamino-2-vinyl-cyclopropyl)-phenyl-phosphinic acid ethyl ester | GILEAD SCIENCES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090306095-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-20090306095-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-20090233975-A1 | Hair resiliency/body improver and hair cosmetic | SHISEIDO COMPANY, LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-7501420-B2 | Composition and antiviral of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501420-B2 | Composition and antiviral of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| CN-101343269-A | 1,2,3-thiadiazoles derivants, synthesis and use thereof | UNIV NANKAI (CN) | 2009-01-14 | — | — | CN | disclosed |
| US-20080311077-A1 | Antiviral Compounds | GILEAD SCIENCES, INC. | 2008-12-18 | — | — | US | disclosed |
| WO-2008130955-A1 | CORROSION-RESISTANT ANISOTROPIC CONDUCTIVE COMPOSITIONS | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| CN-101232863-A | Agent for improving hair tension and toughness and cosmetic for hair | SHISEIDO CO LTD (JP) | 2008-07-30 | — | — | CN | disclosed |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| CN-100384851-C | Epothilone derivatives | NOVARTIS AG (CH) | 2008-04-30 | — | — | CN | disclosed |
| EP-1911750-A1 | AGENT FOR IMPROVEMENT IN BOUNCE/BODY OF HAIR, AND HAIR COSMETIC | Shiseido Company, Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-7354924-B2 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354924-B2 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-7317100-B2 | Epothilone derivatives | NOVARTIS AG (CH) | 2008-01-08 | — | — | US | disclosed |
| CN-101027312-A | Antiviral compounds | GILEAD SCIENCES INC (US) | 2007-08-29 | — | — | CN | disclosed |
| EP-1778702-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060122123-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006020276-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| CN-1732172-A | Epothilone derivatives | NOVARTIS AG (CH) | 2006-02-08 | — | — | CN | disclosed |
| US-20060014796-A1 | Epothilone derivatives | DENNI-DISCHERT DONATIENNE | 2006-01-19 | — | — | US | disclosed |
| EP-1581536-A2 | EPOTHILONE DERIVATIVES | Novartis AG (CH) | 2005-10-05 | — | — | EP | disclosed |
| CN-1208323-C | Alpha-substituted carboxylic acid derivatives | SANKYO CO (JP) | 2005-06-29 | — | — | CN | disclosed |
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2004056832-A2 | EPOTHILONE DERIVATIVES | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | disclosed |
| EP-1377968-A2 | OPTICAL DATA CARRIER THAT CONTAINS A HETEROCYCLIC AZO DYE AS THE LIGHT-ABSORBING COMPOUND IN THE INFORMATION LAYER | Bayer Chemicals AG (DE) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
| US-20030006516-A1 | Optical data storage medium containing a heterocyclic azo dye as the light-absorbing compound in the information layer | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-09 | — | — | US | disclosed |
| WO-2002080152-A2 | OPTICAL DATA CARRIER THAT CONTAINS A HETEROCYCLIC AZO DYE AS THE LIGHT-ABSORBING COMPOUND IN THE INFORMATION LAYER | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-10 | — | — | WO | disclosed |
| CN-1353694-A | Alpha-substituted carboxylic acid derivatives | SANKYO CO (JP) | 2002-06-12 | — | — | CN | disclosed |
| US-5625072-A | TREATING HIV INFECTIONS | ABBOTT LABORATORIES (US) | 1997-04-29 | — | — | US | disclosed |
| US-5578711-A | Process for the preparation of dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1996-11-26 | — | — | US | disclosed |
| US-5541299-A | Process for the preparation of dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1996-07-30 | — | — | US | disclosed |
| US-5502171-A | Process for the preparation of dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1996-03-26 | — | — | US | disclosed |
| WO-1995015955-A1 | 2,4-DIAMINOTHIAZOLES AND THEIR PRODUCTION | BASF AKTIENGESELLSCHAFT (DE) | 1995-06-15 | — | — | WO | disclosed |
| US-4908435-A | Aromatic disazo compounds having strong infra-red absorption | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-03-13 | — | — | US | disclosed |
| US-4908435-A | Aromatic disazo compounds having strong infra-red absorption | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-03-13 | — | — | US | disclosed |